Acne

Olansky Dermatology & Aesthetics welcomes physician assistant, expands hours

Retrieved on: 
Tuesday, April 9, 2024
Psoriasis, Skin cancer, Patient, Mohs surgery, Aesthetics, Quality of life, Suite, Dermatology, Acne, Family

ATLANTA, April 09, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics –Georgia’s top-rated dermatology practice– welcomes physician assistant Kathryn “Katie” Shea to its Buckhead location.

Key Points: 
  • ATLANTA, April 09, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics –Georgia’s top-rated dermatology practice– welcomes physician assistant Kathryn “Katie” Shea to its Buckhead location.
  • This addition to the practice’s acclaimed staff allows Olansky Dermatology & Aesthetics the ability to offer new, expanded hours at its Buckhead location, a first for Atlanta area dermatology.
  • She has extensive experience in dermatology and urgent care medicine, and she is a member of the Georgia Association of Physician Assistants, American Academy of Physician Assistants, and Georgia Dermatology Physician Assistants.
  • “We strive to offer our patients the best providers possible,” says Dr. Jodi Ganz, physician partner at Olansky Dermatology & Aesthetics, “By growing our staff, it allows us to better meet patients where they are and provide additional hours for better flexibility.”
    Olansky Dermatology & Aesthetics is your dermatology solution.

Bestqool Launches Innovative Red Light Therapy Devices for Eczema Relief

Retrieved on: 
Friday, April 5, 2024
Skin care, Fibroblast, Health, Certification, RLT, Psoriasis, Adenosine triphosphate, Cell, Serotonin, Patient, Photobiology, Tissue, Rosacea, Mitochondrion, Mental health, History, Red, Quality of life, Dermatitis, Itch, Keratinocyte, Acne, Skin, Pollution, Erythema, Cytokine, Irritation, ATP, Immune system, Recurrence, Fatigue, Swelling, FDA, Waste, Medical device

Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.

Key Points: 
  • Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.
  • Combining red light therapy with topical ointments can be a complementary approach for effective eczema treatment.
  • Bestqool's latest range of portable red light therapy devices are designed to be both convenient and effective for home use.
  • Adding red light therapy to daily care and prevention can repair both inside and outside by lowering eczema recurrence and improving the quality of life.

Bestqool Revolutionizes Outdoor Activities with Innovative Red Light Therapy Devices

Retrieved on: 
Wednesday, April 3, 2024
RLT, Psoriasis, Motivation, Exercise, Chemical oxygen demand, System, Mitochondrion, Motion, Joint, Life, Athlete, Acne, Facial muscles, Skin, Oxygen, Red light, Health, Low-level laser therapy, Medical imaging

Seattle, Washington, April 03, 2024 (GLOBE NEWSWIRE) -- Bestqool has announced its innovative approach to integrating Red Light Therapy (RLT) with outdoor exercises and sports routines.

Key Points: 
  • Seattle, Washington, April 03, 2024 (GLOBE NEWSWIRE) -- Bestqool has announced its innovative approach to integrating Red Light Therapy (RLT) with outdoor exercises and sports routines.
  • Red Light Therapy is an advanced therapy mode that uses low-level wavelengths of red light to focus on the skin or deeper tissues, as needed to help resolve their related issues.
  • [2]
    Because of the invention of several hand-held devices, using Red Light Therapy within the comforts of your home has also been made possible.
  • When it comes to talking about top-notch, great-quality hand-held Red Light Therapy devices, Bestqool is your ultimate solution.

STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings

Retrieved on: 
Wednesday, March 27, 2024
Growth, Webcast, Tax, International, Bank statement, Dermatology, DTC, Acne, Direct, Annual report, Report, Interest, Safety, SSKN, ID, Marketing, STRATA, Video game

Global recurring revenues for the fourth quarter of 2023 were $5.6 million, as compared to global recurring revenues of $6.5 million for the fourth quarter of 2022.

Key Points: 
  • Global recurring revenues for the fourth quarter of 2023 were $5.6 million, as compared to global recurring revenues of $6.5 million for the fourth quarter of 2022.
  • Equipment revenues were $3.1 million for the fourth quarter of 2023, as compared to $4.1 million for the fourth quarter of 2022.
  • Selling and marketing costs for the fourth quarter of 2023 were $2.8 million, as compared to $3.8 million for the fourth quarter of 2022.
  • Other expenses for the fourth quarter of 2023 were $0.4 million, compared to $0.2 million for the fourth quarter of 2022.

NOVEL 2,910 nm ULTRACLEAR® LASER FROM ACCLARO MEDICAL HITS NEW HEIGHTS AT ASLMS 2024, THE PREMIER GLOBAL CONFERENCE ON ENERGY-BASED MEDICINE AND SCIENCE

Retrieved on: 
Tuesday, April 9, 2024
Laser, Expert, Trial of the century, Master of Science, Acne, Treatment, Society, Skin, Safety, FAAD, Ageing, 3D printing

SMITHFIELD, R.I., April 9, 2024 /PRNewswire/ -- Acclaro Medical proudly announces new clinical study results on nasal contouring, acne scarring, facial resurfacing, facial and neck rejuvenation with stem cell extract and UltraClear® Laser-Coring™  will be presented at the  American Society for Laser Medicine and Surgery (ASLMS) global conference, to be held April 11-14, 2024 in Baltimore, MD. UltraClear Laser is acclaimed by aesthetic laser specialists as a game-changer in combating the signs of aging and the effects of gravity with its unrivaled cosmetic results accompanied by patient comfort, rapid healing and superb safety across all skin tones, including skin of color and tanned skin.

Key Points: 
  • UltraClear Laser is acclaimed by aesthetic laser specialists as a game-changer in combating the signs of aging and the effects of gravity with its unrivaled cosmetic results accompanied by patient comfort, rapid healing and superb safety across all skin tones, including skin of color and tanned skin.
  • "We are thrilled that UltraClear laser is taking center stage with its latest clinical study data, outstanding outcomes and innovative Laser-Coring™ techniques at this year's ASLMS meeting," said Shlomo Assa, MSc, Acclaro Medical's President and Chief Technology Officer.
  • "Our strong presence exemplifies the bold trajectory and compelling value that UltraClear brings to the future of aesthetic laser skin solutions."
  • In addition to the scientific presentations, the company will also sponsor educational events focused on these and other UltraClear laser applications.

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne

Retrieved on: 
Tuesday, April 9, 2024
AbbVie, Antioxidant, MSRP, Nicotinamide, Physician, Patient, ABBV, Senior, Trial of the century, Acne, Skin, Aloe, Yale University, Salicylic acid, Cosmetics

The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin.

Key Points: 
  • The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin.
  • "The formulations of the new products continue the legacy of promoting skin health and addressing key patient concerns like acne."
  • In clinical studies, participants who used the SkinMedica® Acne Clarifying Treatment and Pore Purifying Gel Cleanser noticed clearer skin while reporting that the products did not dry their skin out.
  • "My patients often find themselves in a bind when choosing acne products that treat acne but don't compromise the skin barrier.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, March 25, 2024
Research, FASN, Fatty liver disease, Congress, Exercise, Progression-free survival, F2, Patient, SAN, Food and Drug Administration, F3, G&A, IPO, Obesity, IND, Acne, Bevacizumab, Glioblastoma, Fibrosis, Clinical trial, NASH, FDA, Drug development, Pharmaceutical industry

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31, 2023, and provided corporate updates.

Key Points: 
  • In January 2024, Sagimet sold 9,000,000 shares of its Series A common stock in an underwritten public offering and received $104.7 million in net proceeds.
  • In November 2023, Sagimet presented preclinical data evaluating denifanstat alone or in combination with semaglutide in mouse models of MASH at the 7th Obesity and NASH Drug Development Summit.
  • In October 2023, Sagimet’s license partner for China, Ascletis Bioscience Co. Ltd. (Ascletis), presented Phase 2 topline results at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany.
  • In July 2023, Sagimet closed an upsized IPO of Series A common stock, at a public offering price of $16.00 per share.

Clinique Launches in the U.S. Amazon Premium Beauty Store

Retrieved on: 
Wednesday, March 27, 2024
Women, Men, Technology, Electronic Commerce, Online Retail, Consumer, Cosmetics, Retail, Honey, Education, Hyperpigmentation, State, Allergy, Red, Dermatology, Acne, Dehydration, Skin, Safety, Clinique, Consultant

Clinique marks the first of a select few brands within The Estée Lauder Companies’ portfolio to open a storefront in the U.S. Amazon Premium Beauty store.

Key Points: 
  • Clinique marks the first of a select few brands within The Estée Lauder Companies’ portfolio to open a storefront in the U.S. Amazon Premium Beauty store.
  • Developed with Clinique’s Guiding Dermatologists, this interactive questionnaire in Amazon Premium Beauty will custom-fit a skincare regimen for Clinique’s consumers, ensuring a simplified and personalized skincare journey, with recommended products available for purchase from Amazon’s Premium Beauty store.
  • “We are delighted to introduce Clinique to new consumers in the U.S and make it accessible for the beauty-savvy community in the Amazon Premium Beauty store,” said Michelle Freyre, Global Brand President, Clinique.
  • “Clinique is a beauty brand revered around the world, drawing on a rich heritage of dermatological expertise, and beloved across generations of customers,” said Melis del Rey, G.M., Amazon U.S. Stores Beauty, Baby, and Beauty Technology.